Clinical Trials
16 trialsNCT02354547 2026-05-08
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
SynerGene Therapeutics, Inc.
Phase 1 Suspended
NCT05421897 2026-01-29
RAPID
Children's Hospital Los Angeles
Phase 1 Active not recruiting
NCT04239092 2025-07-17
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
Phase 1 Terminated
NCT00361803 2017-11-17
Topotecan Pharmacokinetic Characterization Study
GlaxoSmithKline
Phase 1 Completed
NCT00483860 2017-11-13
A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function
GlaxoSmithKline
Phase 1 Completed
NCT00117013 2017-07-02
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00553189 2017-07-02
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00422682 2016-06-10
A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT01683149 2016-03-04
Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00770536 2015-09-29
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Amgen
Phase 1 Completed
NCT00250094 2011-09-07
Clinical Benefit of Topoisomerase Downregulation
New Mexico Cancer Research Alliance
Phase 1 Completed
NCT00193583 2011-05-04
Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00320983 2010-01-07
Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer
University of New Mexico
Phase 1 Completed
NCT00412503 2009-08-07
Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT00193570 2009-01-23
Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00006199 2005-06-24
Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)
National Center for Research Resources (NCRR)
Phase 1 Unknown